Search: L773:2688 4526
> (2021) >
Systematic review o...
-
Russell, BethKings Coll London, Sch Canc & Pharmaceut Sci, Dept Translat Oncol & Urol Res, London, England.,Department of Translational Oncology and Urology Research School of Cancer and Pharmaceutical Sciences King's College London London UK
(author)
Systematic review of the association between socioeconomic status and bladder cancer survival with hospital type, comorbidities, and treatment delay as mediators
- Article/chapterEnglish2021
Publisher, publication year, extent ...
-
2021-01-07
-
John Wiley & Sons,2021
-
electronicrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-523448
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-523448URI
-
https://doi.org/10.1002/bco2.65DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-196211URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:235475135URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:for swepub-publicationtype
Notes
-
ObjectivesTo review the current evidence on the relationship between three proposed mediators (comorbidities, hospital type, and treatment delays) for the relationship between socioeconomic status (SES) and bladder cancer survival.Materials and methodsSix different searches using OVID (Medline and Embase) were carried out to collate information available between the proposed mediators with both SES and survival in bladder cancer. This systematic review was conducted according to a pre-defined protocol and in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.ResultsA total of 49 studies were included in the review across the six searches (one appeared in two searches). There was a wealth of studies investigating the relationship between each of the proposed mediators with survival in bladder cancer patients. In general, a higher SES, lower comorbidities, and a larger hospital volume were all found to be associated with a decreased risk of death in bladder cancer patients. There was, however, a paucity of studies investigating the associations between these mediators and SES in bladder cancer patients.ConclusionsTo gain a deeper understanding of the relationship between SES and survival identified in several observational studies, further investigations into the relationship between the proposed mediators and SES are warranted. Moreover, modifiable mediators, eg, treatment delay, highlight the importance of the standardization of clinical care across SES groups for all bladder cancer patients.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Häggström, ChristelUmeå universitet,Uppsala universitet,Endokrinkirurgi,Umeå Univ, Dept Publ Hlth & Clin Med, Umeå, Sweden.,Avdelningen för medicin,Department of Surgical Sciences Uppsala University Uppsala Sweden(Swepub:umu)chlham02
(author)
-
Holmberg, LarsUppsala universitet,Endokrinkirurgi,Kings Coll London, Sch Canc & Pharmaceut Sci, Dept Translat Oncol & Urol Res, London, England.,Department of Translational Oncology and Urology Research School of Cancer and Pharmaceutical Sciences King's College London London UK; Department of Surgical Sciences Uppsala University Uppsala Sweden(Swepub:uu)larsholmb
(author)
-
Liedberg, FredrikSkane Univ Hosp, Dept Urol, Malmö, Sweden.;Lund Univ, Inst Translat Med, Malmö, Sweden.,Department of Urology Skåne University Hospital Malmö Sweden; Institution of Translational Medicine Lund University Malmö Sweden
(author)
-
Gårdmark, TrulsKarolinska Institutet,Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Stockholm, Sweden.
(author)
-
Bryan, Richard T.Univ Birmingham, Inst Canc & Genom Sci, Birmingham, England.,Institute of Cancer and Genomic Sciences The University of Birmingham Birmingham UK
(author)
-
Kumar, PardeepRoyal Marsden NHS Fdn Trust, London, England.,The Royal Marsden NHS Foundation Trust London UK
(author)
-
Van Hemelrijck, MiekeKings Coll London, Sch Canc & Pharmaceut Sci, Dept Translat Oncol & Urol Res, London, England.,Department of Translational Oncology and Urology Research School of Cancer and Pharmaceutical Sciences King's College London London UK
(author)
-
Kings Coll London, Sch Canc & Pharmaceut Sci, Dept Translat Oncol & Urol Res, London, England.Department of Translational Oncology and Urology Research School of Cancer and Pharmaceutical Sciences King's College London London UK
(creator_code:org_t)
Related titles
-
In:BJUI Compass: John Wiley & Sons2:3, s. 140-1582688-4526
Internet link
Find in a library
To the university's database